Drug Profile

AB 101 - Arbutus Biopharma

Alternative Names: AB-101 - Arbutus Biopharma

Latest Information Update: 26 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Arbutus Biopharma
Class Antivirals; Small molecules
Mechanism of Action Programmed cell death-1 ligand-1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I Hepatitis B

Most Recent Events

14 May 2025 Updated adverse events and pharmacodynamics data from a phase Ia/Ib trial in Hepatitis B released by Arbutus Biopharma
06 Nov 2024 Updated pharmacodynamics data from a phase Ia/Ib trial in Hepatitis B released by Arbutus Biopharma
02 May 2024 Efficacy and adverse events data from a phase Ia/Ib trial in Hepatitis B released by Arbutus Biopharma

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com